Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
AIO-Studien
Berlin, Berlin, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
AIO-Studien-gGmbH is currently managing multi-center phase 1/2 clinical trials in Germany, notably the GOBLET study, testing combinations of pelareorep (an oncolytic immunotherapeutic virus) with checkpoint inhibitors (atezolizumab) and chemotherapies in gastrointestinal cancers. Initial safety data have been positive, and several cohorts have advanced based on efficacy markers, including robust overall response rates in metastatic pancreatic cancer cohorts[2][4][5].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculeAntibodyImmuno-oncolytic virus
- Industry
- Academic Hospital/University/Research
02
Partnerships
Beyond the preview
Go deeper on AIO-Studien.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIO-Studien.